Piper Sandler Assumes Regeneron Pharmaceuticals at Overweight, Announces Price Target of $875

Piper Sandler analyst Biren Amin has initiated coverage of Regeneron Pharmaceuticals (NASDAQ: REGN) with an Overweight rating. The firm has set a price target of $875 for the company's stock.